Hypoxia contributes to tumor progression, abnormal blood vessel formation, immune suppression, and therapeutic resistance. Although hypoxia is traditionally viewed as the primary driver of glycolysis, intrinsic oncogenic signaling, mitochondrial dysfunction, and epigenetic reprogramming also stimulate glycolysis indepe...
Ning Kang, Yu-Zhuo Wang· Communications Biology· 0 citations
Lineage plasticity underlies therapeutic resistance in cancer1,2, yet the translational mechanisms that enable this phenotypic flexibility remain largely unknown. Here using prostate cancer as a model of lineage dependence, we performed unbiased small RNA sequencing and identified tRNA1Arg(UCU) as a regulator of lineag...
Y. Kim, Sonali Arora, D. Young et al.· Nature· 0 citations
A deep learning model that leverages interpretable cellular features to improve feature extraction from H&E-stained tissue sections (NEURAL-PC) and represents an extensively validated diagnostic and prognostic model for advanced prostate cancer.
Zhi-Jun Chen, Erolcan Sayar, D. Guevara et al.· JCI Insight· 0 citations
Combined BET bromodomain and DNA methyltransferase (DNMT) inhibition was more effective than single-agent treatment in suppressing growth of TP53/RB1-loss models exhibiting a stem-like or NEPC program.
W. Storck, Diana Flores, A. Kumaraswamy et al.· JCI Insight· 0 citations
It is demonstrated that DNMT3B is required for both the initiation and maintenance of the NEPC phenotype, and its inhibition suppresses NEPC growth and differentiation, highlighting it as a promising therapeutic target for treatment-resistant disease.
Yunsol Jo, H. Jung, Zi-Qin Wang et al.· Molecular Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
